Novartis Ag (NVS) Tax Provisions (2009 - 2026)
Novartis Ag (NVS) posted Tax Provisions of $1.0 billion for Q2 2026, up 248.17% sequentially from -$683.0 million in Q1 2026, and up 99.61% YoY from $507.0 million in Q2 2025.
Novartis Ag (NVS) Tax Provisions (2009 - 2026) Analysis & Trends
Novartis Ag has reported Tax Provisions for 12 years, with the latest figure at $1.0 billion in Q2 2026.
- Quarterly Tax Provisions rose 99.61% year-over-year to $1.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$751.0 million (up 50.82% YoY) and the FY2025 annual result came in at $2.4 billion, up 40.21% from the prior year.
- Tax Provisions grew to $1.0 billion in Q2 2026 per NVS's latest filing, from -$683.0 million in the prior quarter.
- Over five years, Tax Provisions peaked at $1.0 billion in Q2 2026 and troughed at -$1.0 billion in Q4 2024.
- A 5-year average of -$381.4 million and a median of -$422.0 million in 2023 frame the typical range for Tax Provisions.
- The sharpest annual moves came in 2024 and 2025: Tax Provisions tumbled 412.82% in 2024, then jumped 185.21% in 2025.
- Over 5 years, Tax Provisions stood at -$874.0 million in 2022, then grew by 7.09% to -$812.0 million in 2023, then decreased by 27.59% to -$1.0 billion in 2024, then rose by 21.43% to -$814.0 million in 2025, then surged by 224.32% to $1.0 billion in 2026.
- According to Business Quant data, Tax Provisions over the past three periods registered $1.0 billion, -$683.0 million, and -$814.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1.21 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 662.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 654.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 1.01 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 291.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 393.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 242.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -407.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 266.99 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -524.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.01 Bn |
| Mar 31, 2026 | -683.00 Mn |
| Dec 31, 2025 | -814.00 Mn |
| Sep 30, 2025 | -266.00 Mn |
| Jun 30, 2025 | 507.00 Mn |
| Mar 31, 2025 | -798.00 Mn |
| Dec 31, 2024 | -1.04 Bn |
| Sep 30, 2024 | -200.00 Mn |
| Jun 30, 2024 | -595.00 Mn |
| Mar 31, 2024 | -441.00 Mn |
| Dec 31, 2023 | -812.00 Mn |
| Sep 30, 2023 | -39.00 Mn |
| Jun 30, 2023 | -403.00 Mn |
| Mar 31, 2023 | -370.00 Mn |
| Dec 31, 2022 | -874.00 Mn |
| Sep 30, 2022 | -257.00 Mn |
| Jun 30, 2022 | -347.00 Mn |
| Mar 31, 2022 | -450.00 Mn |
| Dec 31, 2021 | -1.00 Bn |
| Sep 30, 2021 | -472.00 Mn |